Characteristics of 119 recipients of allogeneic HSCT with pp65 antigenemia
| . | n . | % . |
|---|---|---|
| Total | 119 | 100 |
| Age (median, range) (y) | 41 (3-65) | |
| Gender | ||
| Female | 55 | 46 |
| Male | 64 | 54 |
| Underlying disease | ||
| Acute leukemia | 42 | 35 |
| CML | 43 | 36 |
| Myelodysplasia | 13 | 11 |
| Non-Hodgkin lymphoma/Hodgkin disease multiple myeloma | 7 | 6 |
| Nonmalignant diseases | 14 | 12 |
| Disease risk | ||
| Nonadvanced | 65 | 55 |
| Advanced | 54 | 45 |
| CMV serostatus | ||
| D+/R+ | 52 | 44 |
| D+/R− | 62 | 52 |
| D−/R+ | 5 | 4 |
| Conditioning regimen | ||
| Cyclophosphamide + TBI | 67 | 56 |
| Cyclophosphamide + busulfan + TBI | 5 | 42 |
| Other with TBI | 12 | 10 |
| Busulfan + cyclophosphamide | 33 | 28 |
| Other without TBI | 2 | 2 |
| Donor type | ||
| Matched related | 54 | 45 |
| Mismatched related | 14 | 12 |
| Unrelated | 51 | 43 |
| GVHD prophylaxis | ||
| Cyclosporine | 6 | 5 |
| Cyclosporine + MTX | 88 | 74 |
| FK506 + MTX | 14 | 12 |
| Other | 11 | 9 |
| Acute GVHD | ||
| Grades 0-1 | 27 | 23 |
| Grades 2-4 | 92 | 77 |
| . | n . | % . |
|---|---|---|
| Total | 119 | 100 |
| Age (median, range) (y) | 41 (3-65) | |
| Gender | ||
| Female | 55 | 46 |
| Male | 64 | 54 |
| Underlying disease | ||
| Acute leukemia | 42 | 35 |
| CML | 43 | 36 |
| Myelodysplasia | 13 | 11 |
| Non-Hodgkin lymphoma/Hodgkin disease multiple myeloma | 7 | 6 |
| Nonmalignant diseases | 14 | 12 |
| Disease risk | ||
| Nonadvanced | 65 | 55 |
| Advanced | 54 | 45 |
| CMV serostatus | ||
| D+/R+ | 52 | 44 |
| D+/R− | 62 | 52 |
| D−/R+ | 5 | 4 |
| Conditioning regimen | ||
| Cyclophosphamide + TBI | 67 | 56 |
| Cyclophosphamide + busulfan + TBI | 5 | 42 |
| Other with TBI | 12 | 10 |
| Busulfan + cyclophosphamide | 33 | 28 |
| Other without TBI | 2 | 2 |
| Donor type | ||
| Matched related | 54 | 45 |
| Mismatched related | 14 | 12 |
| Unrelated | 51 | 43 |
| GVHD prophylaxis | ||
| Cyclosporine | 6 | 5 |
| Cyclosporine + MTX | 88 | 74 |
| FK506 + MTX | 14 | 12 |
| Other | 11 | 9 |
| Acute GVHD | ||
| Grades 0-1 | 27 | 23 |
| Grades 2-4 | 92 | 77 |
CML, chronic myelocytic leukemia; MTX, methotrexate.